Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions

      Comparative studies evaluating traditional versus newer antianginal (AA) medications in chronic stable angina pectoris (CSA) on cardiovascular (CV) outcomes and utilization are limited, particularly in patients with diabetes mellitus (DM). Claims data (2008 to 2012) were analyzed using a commercial database. Patients with CSA receiving a β blocker (BB), calcium channel blocker (CCB), long-acting nitrate (LAN), or ranolazine were identified and followed for 12 months after a change in AA therapy. Patients on traditional AA medications were required to have concurrent sublingual nitroglycerin. Therapy change was defined as adding or switching to another traditional AA medication or ranolazine to identify patients whose angina was inadequately controlled with previous therapy. Four groups were identified (BB, CCB, LAN, or ranolazine users) and matched on relevant characteristics. A DM subset was identified. Logistic regression compared revascularization at 30, 60, 90, 180, and 360 days. Negative binomial regression compared all-cause, CV-, and DM-related (in the DM cohort) health care utilization. A total of 8,008 patients were identified with 2,002 patients in each matched group. Majority were men (mean age 66 years). A subset of 3,724 patients with DM (BB, n = 933; CCB, n = 940; LAN, n = 937; and ranolazine, n = 914) resulted from this cohort. Compared to ranolazine in the overall cohort, traditional AA medication exhibited greater odds for revascularization and higher rates in all-cause outpatient, emergency room visits, inpatient length of stay, and CV-related emergency room visits. In the DM cohort, ranolazine demonstrated similar benefits over traditional AA medication. In conclusion, ranolazine use in patients with inadequately controlled chronic angina is associated with less revascularization and all-cause and CV-related health care utilization compared to traditional AA medication.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Phelps C.E.
        • Buysman E.K.
        • Gomez Rey G.
        Costs and clinical outcomes associated with use of ranolazine for treatment of angina.
        Clin Ther. 2012; 34: 1395-1407
        • Ling H.
        • Packard K.A.
        • Burns T.L.
        • Hilleman D.E.
        Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
        Am J Cardiovasc Drugs. 2013; 13: 407-412
        • Mozaffarian D.
        • Benjamin E.J.
        • Go A.S.
        • Arnett D.K.
        • Blaha M.J.
        • Cushman M.
        • de Ferranti S.
        • Després J.P.
        • Fullerton H.J.
        • Howard V.J.
        • Huffman M.D.
        • Judd S.E.
        • Kissela B.M.
        • Lackland D.T.
        • Lichtman J.H.
        • Lisabeth L.D.
        • Liu S.
        • Mackey R.H.
        • Matchar D.B.
        • McGuire D.K.
        • Mohler 3rd, E.R.
        • Moy C.S.
        • Muntner P.
        • Mussolino M.E.
        • Nasir K.
        • Neumar R.W.
        • Nichol G.
        • Palaniappan L.
        • Pandey D.K.
        • Reeves M.J.
        • Rodriguez C.J.
        • Sorlie P.D.
        • Stein J.
        • Towfighi A.
        • Turan T.N.
        • Virani S.S.
        • Willey J.Z.
        • Woo D.
        • Yeh R.W.
        • Turner M.B.
        • American Heart Association Statistics Committee and Stroke Statistics Subcommittee
        Heart disease and stroke statistics--2015 update: a report from the American Heart Association.
        Circulation. 2015; 131: e29-e322
        • Fihn S.D.
        • Gardin J.M.
        • Abrams J.
        • Berra K.
        • Blankenship J.C.
        • Dallas A.P.
        • Douglas P.S.
        • Foody J.M.
        • Gerber T.C.
        • Hinderliter A.L.
        • King 3rd, S.B.
        • Kligfield P.D.
        • Krumholz H.M.
        • Kwong R.Y.
        • Lim M.J.
        • Linderbaum J.A.
        • Mack M.J.
        • Munger M.A.
        • Prager R.L.
        • Sabik J.F.
        • Shaw L.J.
        • Sikkema J.D.
        • Smith Jr., C.R.
        • Smith Jr., S.C.
        • Spertus J.A.
        • Williams S.V.
        • Anderson J.L.
        2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2012; 60: e44-e164
      1. Healthcare Costs and Utilization Project. Chronic condition indicator for ICD-9-cm. Available at: Accessed on July 10, 2015.

        • Choudhary N.K.
        • Shrank W.
        • Levin R.L.
        • Lee J.L.
        • Jan S.A.
        • Brookhart M.A.
        • Solomon D.H.
        Measuring concurrent adherence to multiple related medications.
        Am J Manag Care. 2009; 15: 457-464
        • Arnold S.V.
        • Morrow D.A.
        • Lei Y.
        • Cohen D.J.
        • Mahoney E.M.
        • Braunwald E.
        • Chan P.S.
        Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.
        Circ Cardiovasc Qual Outcomes. 2009; 2: 344-353
        • Kosiborod M.
        • Arnold S.V.
        • Spertus J.A.
        • McGuire D.K.
        • Li Y.
        • Yue P.
        • Ben-Yehuda O.
        • Katz A.
        • Jones P.G.
        • Olmsted A.
        • Belardinelli L.
        • Chaitman B.R.
        Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina).
        J Am Coll Cardiol. 2013; 61: 2038-2045
        • Timmis A.D.
        • Chaitman B.R.
        • Crager M.
        Effects of ranolazine on exercise tolerance and hba1c in patients with chronic angina and diabetes.
        Eur Heart J. 2006; 27: 42-48
        • Arnold S.V.
        • McGuire D.K.
        • Spertus J.A.
        • Li Y.
        • Yue P.
        • Ben-Yehuda O.
        • Belardinelli L.
        • Jones P.G.
        • Olmsted A.
        • Chaitman B.R.
        • Kosiborod M.
        Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin a1c.
        Am Heart J. 2014; 168: 457-465
        • Arnold S.V.
        • Kosiborod M.
        • Li Y.
        • Jones P.G.
        • Yue P.
        • Belardinelli L.
        • Spertus J.A.
        Comparison of the Seattle Angina Questionnaire with daily angina diary in the TERISA clinical trial.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 844-850
        • Morrow D.A.
        • Scirica B.M.
        • Chaitman B.R.
        • McGuire D.K.
        • Murphy S.A.
        • Karwatowska-Prokopczuk E.
        • McCabe C.H.
        • Braunwald E.
        Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
        Circulation. 2009; 119: 2032-2039
        • Chisholm J.W.
        • Goldfine A.B.
        • Dhalla A.K.
        • Braunwald E.
        • Morrow D.A.
        • Karwatowska-Prokopczuk E.
        • Belardinelli L.
        Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome.
        Diabetes Care. 2015; 33: 1163-1168
        • Eckel R.H.
        • Henry R.R.
        • Yue P.
        • Dhalla A.
        • Wong P.
        • Jochelson P.
        • Belardinelli L.
        • Skyler J.S.
        Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes.
        Diabetes Care. 2015; 38: 1189-1196
        • Bangalore S.
        • Steg G.
        • Deedwania P.
        • Crowley K.
        • Eagle K.A.
        • Goto S.
        • Ohman E.M.
        • Cannon C.P.
        • Smith S.C.
        • Zeymer U.
        • Hoffman E.B.
        • Messerli F.H.
        • Bhatt D.L.
        β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
        JAMA. 2012; 308: 1340-1349
        • Bangalore S.
        • Bhatt D.L.
        • Steg G.
        • Weber M.A.
        • Boden W.E.
        • Hamm C.W.
        • Montalescot G.
        • Hsu A.
        • Fox K.A.
        β-Blocker and cardiovascular events in patients with and without myocardial infarction. Post hoc analysis from the CHARISMA trial.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 872-881
        • Andersson C.
        • Shilane D.
        • Go A.S.
        • Chang T.I.
        • Kazi D.
        • Solomon M.D.
        • Boothroyd D.B.
        • Hlatky M.A.
        Beta-blocker therapy and cardiac events among newly diagnosed coronary heart disease.
        J Am Coll Cardiol. 2014; 64: 247-252
      2. Package Insert Ranolazine, Extended Release Tablets, Ranexa. Gilead Sciences, Foster City, CA.2013
        • Rothberg M.B.
        • Sivalingam S.K.
        • Kleppel R.
        • Schweiger M.
        • Hu B.
        • Sepucha K.R.
        Informed decision making for percutaneous coronary intervention for stable coronary disease.
        JAMA Intern Med. 2015; 175: 1199-1206
        • Kempf J.
        • Buysman E.
        • Brixner D.
        Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting.
        Am Health Drug Benefits. 2011; 46: 353-361
        • Lu Z.
        • Jiang Y.P.
        • Wu C.Y.
        • Ballou L.M.
        • Liu S.
        • Carpenter E.S.
        • Rosen M.R.
        • Cohen I.S.
        • Lin R.Z.
        Increased persistent sodium current due to decreased PI3K signaling contributes to qt prolongation in the diabetic heart.
        Diabetes. 2013; 62: 4257-4265